Toripalimab combined with Bevacizumab

COMBINATION_PRODUCT2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Advanced Hepatocellular Carcinoma (HCC)

Phase 2

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

CompletedNCT04605796

Shanghai Junshi Bioscience Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2020-04-10End: 2023-05-30Updated: 2026-07-09

Phase 3

Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC

CompletedNCT04723004

Shanghai Junshi Bioscience Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2020-10-15End: 2024-05-31Updated: 2026-07-13

Related Papers

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial.

2025-05-205 citations

Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.

Journal of Clinical Oncology2022-01-195 citations